Mar 31, 2021

BeiGene Q1 2021 Earnings Report

Provided gross profit margin ratios for various products.

Key Takeaways

The document provides gross profit margin ratios for Celgene products, Amgen product, BRUKINSA®, and Tislelizumab for different periods. It highlights the financial information prepared in accordance with both PRC GAAP and U.S. GAAP.

Gross profit margin ratios are provided for Celgene products from 2017 to September 30, 2020.

Gross profit margin ratio for Amgen product is available for the nine months ended September 30, 2020.

BRUKINSA® gross profit margin ratios are provided for the nine months ended September 30, 2020 and the year ended December 31, 2019.

Tislelizumab gross profit margin ratio is available for the nine months ended September 30, 2020.

Total Revenue
$606M
Previous year: $52.1M
+1063.8%
EPS
$0.69
Previous year: -$4.7
-114.7%
Gross Profit
$252M
Previous year: -$266M
-194.8%
Cash and Equivalents
$1.9B
Previous year: $3.38B
-43.7%
Free Cash Flow
$82.7M
Previous year: -$363M
-122.8%
Total Assets
$5.82B
Previous year: $4.07B
+43.1%

BeiGene

BeiGene

Forward Guidance

No forward guidance was provided in the document.